243 related articles for article (PubMed ID: 27560448)
1. First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response - systematic review and meta-analysis.
Gurion R; Raanani P; Vidal L; Leader A; Gafter-Gvili A
Acta Oncol; 2016; 55(9-10):1077-1083. PubMed ID: 27560448
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
4. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis.
Fachi MM; Tonin FS; Leonart LP; Aguiar KS; Lenzi L; Figueiredo BC; Fernandez-Llimos F; Pontarolo R
Eur J Cancer; 2018 Nov; 104():9-20. PubMed ID: 30296736
[TBL] [Abstract][Full Text] [Related]
6. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
7. First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.
Vener C; Banzi R; Ambrogi F; Ferrero A; Saglio G; Pravettoni G; Sant M
Blood Adv; 2020 Jun; 4(12):2723-2735. PubMed ID: 32559295
[TBL] [Abstract][Full Text] [Related]
8. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
Jain P; Kantarjian H; Boddu PC; Nogueras-González GM; Verstovsek S; Garcia-Manero G; Borthakur G; Sasaki K; Kadia TM; Sam P; Ahaneku H; O'Brien S; Estrov Z; Ravandi F; Jabbour E; Cortes JE
Blood Adv; 2019 Mar; 3(6):851-861. PubMed ID: 30885996
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
Yilmaz M; Jabbour E
Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132
[TBL] [Abstract][Full Text] [Related]
11. [Chronic myeloid leukemia].
Usui N
Nihon Rinsho; 2014 Jun; 72(6):1068-72. PubMed ID: 25016806
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review and Meta-Analysis of -New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia.
Pan P; Wang L; Wang Y; Shen L; Zheng P; Bi C; Zhang A; Lv Y; Xue Z; Sun M; Sun C; Li J; Jin L; Yao Y
Acta Haematol; 2020; 143(3):204-216. PubMed ID: 31514197
[TBL] [Abstract][Full Text] [Related]
13. Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors.
Atallah E; Mauro MJ; Hochhaus A; Boquimpani C; Minami Y; Maheshwari VK; Saini L; Corbin R; Réa D
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6247-6262. PubMed ID: 36707445
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.
Cha SH; Kim K; Song YK
Acta Oncol; 2023 Dec; 62(12):1767-1774. PubMed ID: 37787749
[TBL] [Abstract][Full Text] [Related]
15. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
16. Current status and novel strategy of CML.
Morita K; Sasaki K
Int J Hematol; 2021 May; 113(5):624-631. PubMed ID: 33782818
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Whalen J; Stillman I; Ambavane A; Felber E; Makenbaeva D; Bolinder B
J Med Econ; 2016; 19(5):445-61. PubMed ID: 26613118
[TBL] [Abstract][Full Text] [Related]
18. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
Cortes J; Rea D; Lipton JH
Am J Hematol; 2019 Mar; 94(3):346-357. PubMed ID: 30394563
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Survival of Patients with Chronic Myeloid Leukemia Treated with Imatinib in the Last 15 Years in Lebanon.
Massoud M; Sakr R; Kerbage F; Makdissi J; Hawi J; Rached L; Nasr F; Chahine G
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S111-S115. PubMed ID: 28760296
[TBL] [Abstract][Full Text] [Related]
20. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
